biostudies-literatureBaptista MJ"la Caixa" FoundationInstituto de Salud Carlos III“la Caixa” FoundationGilead Sciences S.L. SpainFundación Josep Carreras Contra la LeucemiaAgència de Gestió d'Ajuts Universitaris i de Recerca. Generalitat de Catalunya826-840https://www.ebi.ac.uk/biostudies/studies/S-EPMC9828544biostudies-literatureUnknown81(6)The frequency of aggressive subtypes of B-cell non-Hodgkin lymphoma (B-NHL), such as high-grade B-cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH/TH) or Burkitt-like lymphoma (BL) with 11q aberration, is not well known in the HIV setting. We aimed to characterise HIV-associated aggressive B-NHL according to the 2017 WHO criteria, and to identify genotypic and phenotypic features with prognostic impact. Seventy-five HIV-associated aggressive B-NHL were studied by immunohistochemistry (CD10, BCL2, BCL6, MUM1, MYC, and CD30), EBV-encoded RNAs (EBERs), and fluorescence in situ hybridisation (FISH) to evaluate the status of the MYC, BCL2, and BCL6 genes and chromosome 11q. The 2017 WHO classification criteria and the Hans algorithm, for the cell-of-origin classificatiHistopathologyGenetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.PMC98285442017 SGR288PI19/01588GLD19/00121Colomo LMuncunill JGribben JGMoraleda JMFerrandez AMate JLRibera JMAbella ENavarro JTAldamiz TTerol MJMenarguez JGarcia-Caro MCalaminici MMunoz-Marmol AMProvencio MGarcia-Ballesteros CAlcoceba MCliment FMuntanola AAbrisqueta PMartinez-Trillos ATapia GGarcia OBriones JSancho JMMartinez ABaptista MJMontoto SVeloza LGonzalez-Barca EfalseGenetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.The frequency of aggressive subtypes of B-cell non-Hodgkin lymphoma (B-NHL), such as high-grade B-cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH/TH) or Burkitt-like lymphoma (BL) with 11q aberration, is not well known in the HIV setting. We aimed to characterise HIV-associated aggressive B-NHL according to the 2017 WHO criteria, and to identify genotypic and phenotypic features with prognostic impact. Seventy-five HIV-associated aggressive B-NHL were studied by immunohistochemistry (CD10, BCL2, BCL6, MUM1, MYC, and CD30), EBV-encoded RNAs (EBERs), and fluorescence in situ hybridisation (FISH) to evaluate the status of the MYC, BCL2, and BCL6 genes and chromosome 11q. The 2017 WHO classification criteria and the Hans algorithm, for the cell-of-origin classificati2022-01-01T00:00:00Z2022 Dec2025-04-21T18:01:04.925Z2025-04-05T17:02:57.39ZS-EPMC98285443610917210.1111/his.14798